Skip to main content
C

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Filings indexed 503 across all filing types
Latest filing 2023-10-26 Regulatory Filings
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 37 pages 1.2MB
Regulatory Filings
2023-10-26 English
Letter to Shareholders - AGM 1 page 115.4KB
Regulatory Filings
2023-10-26 English
Date of AGM 1 page 241.8KB
Regulatory Filings
2023-10-04 English
Annual Report 2023 54 pages 2.9MB
Regulatory Filings
2023-09-28 English
Appendix 4G and Corporate Governance Statement 26 pages 545.3KB
Regulatory Filings
2023-09-28 English
Cambium Bio - Shareholder Update presentation 16 pages 2.7MB
Regulatory Filings
2023-09-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.